JP2018515513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515513A5 JP2018515513A5 JP2017558542A JP2017558542A JP2018515513A5 JP 2018515513 A5 JP2018515513 A5 JP 2018515513A5 JP 2017558542 A JP2017558542 A JP 2017558542A JP 2017558542 A JP2017558542 A JP 2017558542A JP 2018515513 A5 JP2018515513 A5 JP 2018515513A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody according
- seq
- region
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078658A JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫（ｍｍ）の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167597.2 | 2015-05-13 | ||
| EP15167597 | 2015-05-13 | ||
| PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078658A Division JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫（ｍｍ）の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515513A JP2018515513A (ja) | 2018-06-14 |
| JP2018515513A5 true JP2018515513A5 (enExample) | 2019-06-13 |
| JP7160533B2 JP7160533B2 (ja) | 2022-10-25 |
Family
ID=53174925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558542A Active JP7160533B2 (ja) | 2015-05-13 | 2016-05-13 | 多発性骨髄腫（ｍｍ）の処置 |
| JP2021078658A Pending JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫（ｍｍ）の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078658A Pending JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫（ｍｍ）の処置 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10533057B2 (enExample) |
| EP (1) | EP3294769B1 (enExample) |
| JP (2) | JP7160533B2 (enExample) |
| KR (1) | KR20180008571A (enExample) |
| CN (1) | CN107614530A (enExample) |
| AU (1) | AU2016260895B2 (enExample) |
| CA (1) | CA2984464C (enExample) |
| CY (1) | CY1123982T1 (enExample) |
| DK (1) | DK3294769T3 (enExample) |
| ES (1) | ES2862708T3 (enExample) |
| HR (1) | HRP20210552T1 (enExample) |
| HU (1) | HUE054271T2 (enExample) |
| IL (1) | IL255552B (enExample) |
| LT (1) | LT3294769T (enExample) |
| MX (1) | MX380557B (enExample) |
| PL (1) | PL3294769T3 (enExample) |
| PT (1) | PT3294769T (enExample) |
| RS (1) | RS61668B1 (enExample) |
| RU (1) | RU2723047C2 (enExample) |
| SG (1) | SG11201708691VA (enExample) |
| SI (1) | SI3294769T1 (enExample) |
| SM (1) | SMT202100202T1 (enExample) |
| WO (1) | WO2016180958A1 (enExample) |
| ZA (1) | ZA201708386B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| ES2862708T3 (es) * | 2015-05-13 | 2021-10-07 | Morphosys Ag | Tratamiento del mieloma múltiple (MM) |
| CN109689690B (zh) | 2016-07-15 | 2023-10-03 | 武田药品工业株式会社 | 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料 |
| EP3737702A1 (en) | 2018-01-12 | 2020-11-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| MX2020010144A (es) * | 2018-03-28 | 2020-12-07 | Takeda Pharmaceuticals Co | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| CA3122902A1 (en) * | 2018-12-14 | 2020-06-18 | Morphosys Ag | Antibody formulations |
| KR20210120048A (ko) * | 2019-01-28 | 2021-10-06 | 사노피 | 다발성 골수종의 치료 방법 |
| US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| BRPI0507489A (pt) | 2004-02-06 | 2007-07-10 | Morphosys Ag | anticorpos humanos de anti-cd38 e para os seus usos |
| IL316252A (en) * | 2005-03-23 | 2024-12-01 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| AR053489A1 (es) | 2005-05-24 | 2007-05-09 | Morphosys Ag | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano |
| SG10201400973XA (en) | 2005-10-12 | 2014-08-28 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| PT2641601T (pt) * | 2006-08-07 | 2016-10-14 | Dana Farber Cancer Inst Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib |
| EP3753576A1 (en) * | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PT2580243T (pt) * | 2010-06-09 | 2020-01-22 | Genmab As | Anticorpos contra cd38 humana |
| LT2621531T (lt) * | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| US9738933B2 (en) * | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
| KR20160077155A (ko) * | 2013-10-31 | 2016-07-01 | 사노피 | 인간 암을 치료하기 위한 특이적 항-ｃｄ38 항체 |
| AU2015277494A1 (en) | 2014-06-16 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2016022589A2 (en) * | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| ES2862708T3 (es) * | 2015-05-13 | 2021-10-07 | Morphosys Ag | Tratamiento del mieloma múltiple (MM) |
-
2016
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2016-05-13 SM SM20210202T patent/SMT202100202T1/it unknown
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Ceased
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en not_active Ceased
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
- 2016-05-13 MX MX2017014396A patent/MX380557B/es unknown
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515513A5 (enExample) | ||
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| JP2015514110A5 (enExample) | ||
| JP2016520514A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| JP2018021031A5 (enExample) | ||
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| PE20221337A1 (es) | Anticuerpos trem2 y usos de estos | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| JP2015530399A5 (enExample) | ||
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| JP2015535828A5 (enExample) |